Arcutis Q4 revenue rises 84% on ZORYVE sales, raises FY guidance

Overview

• Biopharmaceutical firm's Q4 2025 net product revenue rose 84% yr/yr, driven by ZORYVE sales

• Company achieved positive operating cash flow in Q4 2025

• Raised 2026 full-year net product sales guidance to $480 mln – $495 mln

Outlook

• Company raised 2026 full-year net product sales guidance to $480 mln – $495 mln

• Company anticipates maintaining positive operating cash flow quarterly going forward

• Arcutis plans sNDA submission for ZORYVE cream in Q2 2026

Result Drivers

• DEMAND FOR ZORYVE - Strong demand for ZORYVE drove 84% year-over-year increase in Q4 net product revenue

• SALES FORCE EXPANSION - Co expanded dermatology sales force to optimize prescriber targeting and deepen ZORYVE adoption

Company press release: ID:nGNX4YZCxf

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is $31.00, about 14.9% above its February 24 closing price of $26.98

• The stock recently traded at 69 times the next 12-month earnings vs. a P/E of 95 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)